Skip to main content
SpringerLink
Log in

Immunotherapy of rheumatoid arthritis using CD4+CD25+ regulatory T cells

  • Chapter
Regulatory T Cells in Inflammation

Part of the book series: Progress in Inflammation Research ((PIR))

  • 514 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Appelboom T, Halberg B (2004) Rheumatoid arthritis and other synovial disorders. In: MC Hochberg, AJ Silman, JS Smolen, ME Weinblatt, MH Weisman (eds): Rheumatology, 3rd ed., Mosby, London, 753–937

    Google Scholar 

  2. Hochberg MC, Spector TD (1990) Epidemiology of rheumatoid arthritis: update. Epidemiol Rev 12: 247–252

    PubMed  Google Scholar 

  3. Hochberg MC (1983) Epidemiology of rheumatoid arthritis in developed countries. J Rheumatol (Suppl) 10: 7–10

    Google Scholar 

  4. Silman AJ, Pearson JE (2002) Epidemiology and genetics of rheumatoid arthritis. Arthritis Res 4(Suppl 3): S265–S272

    PubMed  Google Scholar 

  5. Jarvinen P, Aho K (1994) Twin studies in rheumatic diseases. Semin Arthritis Rheum 1:19–28

    Google Scholar 

  6. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ (1993) Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261:1328–1330

    PubMed  Google Scholar 

  7. Kim WU, Cho ML, Jung YO, Min SY, Park SW, Min DJ, Yoon JH, Kim HY (2004) Type II collagen autoimmunity in rheumatoid arthritis. Am J Med Sci 4: 202–211

    Google Scholar 

  8. Cook AD, Rowley MJ, Mackay IR, Gough A, Emery P (1996) Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 10: 1720–1727

    Google Scholar 

  9. van Eden W (1991) Heat-shock proteins as immunogenic bacterial antigens with the potential to induce and regulate autoimmune arthritis. Immunol Rev 121: 5–28

    PubMed  Google Scholar 

  10. McDevitt H (2000) A new model for rheumatoid arthritis? Arthritis Res 2: 85–89

    PubMed  Google Scholar 

  11. Verheijden GF, Rijnders AW, Bos E, Coenen-de Roo CJ, van Staveren CJ, Miltenburg AM, Meijerink JH, Elewaut D, de Keyser F, Veys E et al (1997) Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 6:1115–1125

    Google Scholar 

  12. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, Soh C, Staines NA, Pappin DJ, Berlo SE et al (2001) The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 3: 1492–1498

    Google Scholar 

  13. Myers LK, Rosloniec EF, Cremer MA, Kang AH (1997) Collagen-induced arthritis, an animal model of autoimmunity. Life Sci 19: 1861–1878

    Google Scholar 

  14. Luross JA, Williams NA (2001) The genetic and immunopathological processes underlying collagen-induced arthritis. Immunology 4: 407–416

    Google Scholar 

  15. Holoshitz J, Matitiau A, Cohen IR (1985) Role of the thymus in induction and transfer of vaccination against adjuvant arthritis with a T lymphocyte line in rats. J Clin Invest 2: 472–477

    Google Scholar 

  16. Cush JJ, Lipsky PE (1988) Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum 10:1230–1238

    Google Scholar 

  17. Kidd P (2003) Thl/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev 3: 223–246

    Google Scholar 

  18. van Roon JA, Bijlsma JW, Lafeber FP (2002) Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr Opin Invest Drugs 7: 1011–1016

    Google Scholar 

  19. Salmon M, Scheel-Toellner D, Huissoon AP, Pilling D, Shamsadeen N, Hyde H, D’Angeac AD, Bacon PA, Emery P, Akbar AN (1997) Inhibition of T cell apoptosis in the rheumatoid synovium. J Clin Invest 3: 439–446

    Google Scholar 

  20. Buckley CD, Amft N, Bradfield PF, Pilling D, Ross E, Arenzana-Seisdedos F, Amara A, Curnow SJ, Lord JM, Scheel-Toellner D et al (2000) Persistent induction of the chemokine receptor CXCR4 by TGF-beta 1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J Immunol 6: 3423–3429

    Google Scholar 

  21. lannone F, Corrigal VM, Panayi GS (1996) CD69 on synovial T cells in rheumatoid arthritis correlates with disease activity. Br J Rheumatol 35: 397

    PubMed  Google Scholar 

  22. Liu MF, Chao SC, Wang CR, Lei HY (2001) Expression of CD40 and CD40 ligand among cell populations within rheumatoid synovial compartment. Autoimmunity 2:107–113

    Google Scholar 

  23. Pacholczyk R, Kraj P, Ignatowicz L (2002) Peptide specificity of thymic selection of CD4+CD25+ T cells. J Immunol 2: 613–620

    Google Scholar 

  24. MacDonald KP, Nishioka Y, Lipsky PE, Thomas R (1997) Functional CD40 ligand is expressed by T cells in rheumatoid arthritis. J Clin Invest 9: 2404–2414

    Google Scholar 

  25. Ranges GE, Sriram S, Cooper SM (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 3: 1105–1110

    Google Scholar 

  26. Levitt NG, Fernandez-Madrid F, Wooley PH (1992) Pristane induced arthritis in mice. IV. Immunotherapy with monoclonal antibodies directed against lymphocyte subsets. J Rheumatol 9: 1342–1347

    Google Scholar 

  27. Van den Broek MF, Van de Langerijt LG, Van Bruggen MC, Billingham ME, Van den Berg WB (1992) Treatment of rats with monoclonal anti-CD4 induces long-term resistance to streptococcal cell wall-induced arthritis. Eur J Immunol 1: 57–61

    Google Scholar 

  28. Pohlers D, Nissler K, Frey O, Simon J, Petrow PK, Kinne RW, Brauer R (2004) Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen-induced arthritis: influence on T helper cell activation. Clin Exp Immunol 3: 409–415

    Google Scholar 

  29. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Light-foot R, Calabrese L, Zelinger DJ, Woody JN (1995) Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 11:1581–1588

    Google Scholar 

  30. van der Lubbe PA, Dijkmans BA, Markusse HM, Nassander U, Breedveld FC (1995) A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 8: 1097–1106

    Google Scholar 

  31. Choy EH, Panayi GS, Emery P, Madden S, Breedveld FC, Kraan MC, Kalden JR, Rascu A, Brown JC, Rapson N, Johnston JM (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 10: 1142–1148

    Google Scholar 

  32. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 20:1907–1915

    Google Scholar 

  33. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, Cohen S, Luggen M, Shergy W, Nuamah I et al (2002) Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum 6: 1470–1479

    Google Scholar 

  34. Kim HJ, Berek C (2000) B cells in rheumatoid arthritis. Arthritis Res 2: 126–131

    PubMed  Google Scholar 

  35. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 25: 2572–2581

    Google Scholar 

  36. Kinne RW, Brauer R, Stuhlmuller B, Palombo-Kinne E, Burmester GR (2000) Macrophages in rheumatoid arthritis. Arthritis Res 3: 189–202

    Google Scholar 

  37. Mulherin D, Fitzgerald O, Bresnihan B (1996) Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1: 115–124

    Google Scholar 

  38. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, Haanen HC, Hofman DM, Albada-Kuipers GA, ter Borg EJ et al. (1996) The effectiveness of early treatment with “second-line” antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 8: 699–707

    Google Scholar 

  39. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, Verburg KM, Isakson PC, Hubbard RC, Geis GS (1999) Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354: 2106–2111

    PubMed  Google Scholar 

  40. Bijlsma JW, Van Everdingen AA, Huisman M, De Nijs RN, Jacobs JW (2002) Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Ann NY Acad Sci 966:82–90

    PubMed  Google Scholar 

  41. Lundberg IE, Grundtman C, Larsson E, Klareskog L (2004) Corticosteroids — from an idea to clinical use. Best Pract Res Clin Rheumatol 1: 7–19

    Google Scholar 

  42. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, Kushner I, Wolfe F (2002) Evidence from clinical trials and long-term observational studies that disease-modifying antirheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology 12: 1346–1356

    Google Scholar 

  43. Breedveld FC, Kalden JR (2004) Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 6: 627–633

    Google Scholar 

  44. Chan ES, Cronstein BN (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res 4: 266–273

    PubMed  Google Scholar 

  45. Cronstein BN (1995) The antirheumatic agents sulphasalazine and methotrexate share an anti-inflammatory mechanism. Br J Rheumatol 34(Suppl 2): 30–32

    PubMed  Google Scholar 

  46. Feldmann M, Maini RN (2001) Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 19: 163–196

    PubMed  Google Scholar 

  47. Feldmann M, Brennan FM, Williams RO, Woody JN, Maini RN (2004) The transfer of a laboratory based hypothesis to a clinically useful therapy: the development of anti-TNF therapy of rheumatoid arthritis. Best Pract Res Clin Rheumatol 1: 59–80

    Google Scholar 

  48. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Hashimoto J, Azuma J, Kishimoto T (2004) Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 6: 1761–1769

    Google Scholar 

  49. Taylor PC (2003) Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 3:323–328

    PubMed  Google Scholar 

  50. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 3:1151–1164

    Google Scholar 

  51. Taams LS, Smith J, Rustin MH, Salmon M, Poulter LW, Akbar AN (2001) Human anergic/suppressive CD4(+)CD25(+) T cells: a highly differentiated and apoptosis-prone population. Eur J Immunol 4: 1122–1131

    Google Scholar 

  52. Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, Sakaguchi S (1999) Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 9: 5317–5326

    Google Scholar 

  53. Stephens LA, Mottet C, Mason D, Powrie F (2001) Human CD4(+)CD25(+) thymocytes and peripheral T cells have immune suppressive activity in vitro. Eur J Immunol 4:1247–1254

    Google Scholar 

  54. Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, Kaiser LR, June CH (2002) Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 9: 4272–4276

    Google Scholar 

  55. Mottet C, Uhlig HH, Powrie F (2003) Cutting edge: cure of colitis by CD4(+)CD25(+) regulatory T cells. J Immunol 8: 3939–3943

    Google Scholar 

  56. Cavani A, Nasorri F, Ottaviani C, Sebastiani S, De Pita O, Girolomoni G (2003) Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals. J Immunol 11: 5760–5768

    Google Scholar 

  57. Suri-Payer E, Amar AZ, Thornton AM, Shevach EM (1998) CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 3: 1212–1218

    Google Scholar 

  58. Shevach EM (2001) Certified professionals: CD4(+)CD25(+) suppressor T cells. J Exp Med 11: F41–F46

    Google Scholar 

  59. Piccirillo CA, Shevach EM (2001) Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 3: 1137–1140

    Google Scholar 

  60. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S (1998) Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 12: 1969–1980

    Google Scholar 

  61. Read S, Malmstrom V, Powrie F (2000) Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2: 295–302

    Google Scholar 

  62. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S (2002) Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2: 135–142

    Google Scholar 

  63. McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, Byrne MC (2002) CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2: 311–323

    Google Scholar 

  64. Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, Morris PJ, Powrie F, Wood KJ (2001) IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 6: 3789–3796

    Google Scholar 

  65. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W (2004) TGF-betal plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 2: 834–842

    Google Scholar 

  66. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM (2003) Conversion of peripheral CD4+. J Exp Med 12: 1875–1886

    Google Scholar 

  67. Zheng SG, Gray JD, Ohtsuka K, Yamagiwa S, Horwitz DA (2002) Generation ex vivo of TGF-beta-producing regulatory T cells from CD4+CD25-precursors. J Immunol 8:4183–4189

    Google Scholar 

  68. Hori S, Nomura T, Sakaguchi S (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057–1061

    PubMed  Google Scholar 

  69. Cederbom L, Hall H, Ivars F (2000) CD4+CD25+ regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells. Eur J Immunol 6: 1538–1543

    Google Scholar 

  70. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV (2004) Cutting Edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 8: 4676–4680

    Google Scholar 

  71. Bardos T, Czipri M, Vermes C, Finnegan A, Mikecz K, Zhang J (2003) CD4+CD25+ immunoregulatory T cells may not be involved in controlling autoimmune arthritis. Arthritis Res Ther 2: R106–R113

    Google Scholar 

  72. Morgan ME, Sutmuller RP, Witteveen HJ, Van Duivenvoorde LM, Zanelli E, Melief CJ, Snijders A, Offringa R, De Vries RR, Toes RE (2003) CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 5:1452–1460

    Google Scholar 

  73. Cao D, Malmstrom V, Baecher-Allan C, Hafler D, Klareskog L, Trollmo C (2003) Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis. Eur J Immunol 1: 215–223

    Google Scholar 

  74. van Amelsfort J, Jacobs K, Bijlsma JW, Lafeber FP, Taams L (2004) CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in presence, phenotype and function between peripheral blood and synovial fluid. Arthritis Rheum 50: 2775–2785

    PubMed  Google Scholar 

  75. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA (2001) CD4+CD25high regulatory cells in human peripheral blood. J Immunol 3: 1245–1253

    Google Scholar 

  76. de Kleer IM, Wedderburn LR, Taams LS, Patel A, Varsani H, Klein M, de Jager W, Pugayung G, Giannoni F, Rijkers G et al (2004) CD4+CD25(bright) regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 10: 6435–6443

    Google Scholar 

  77. Takahashi T, Tagami T, Yamazaki S, Uede T, Shimizu J, Sakaguchi N, Mak TW, Sakaguchi S (2000) Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2: 303–310

    Google Scholar 

  78. Baecher-Allan C, Viglietta V, Hafler DA (2002) Inhibition of human CD4(+) CD25(+high) regulatory T cell function. J Immunol 11: 6210–6217

    Google Scholar 

  79. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G (2001) Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 11: 1303–1310

    Google Scholar 

  80. Jonuleit H, Schmitt E, Stassen M, Tuettenberg A, Knop J, Enk AH (2001) Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J Exp Med 11: 1285–1294

    Google Scholar 

  81. van Roon JA, Glaudemans KA, Bijlsma JW, Lafeber FP (2003) Interleukin 7 stimulates tumour necrosis factor alpha and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2: 113–119

    Google Scholar 

  82. Dolhain RJ, Ter Haar NT, De Kuiper R, Nieuwenhuis IG, Zwinderman AH, Breedveld FC, Miltenburg AM (1998) Distribution of T cells and signs of T-cell activation in the rheumatoid joint: implications for semiquantitative comparative histology. Br J Rheumatol 3: 324–330

    Google Scholar 

  83. Cao D, Vollenhoven RR, Klareskog L, Trollmo C, Malmstrom V (2004) CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 4: R335–R346

    Google Scholar 

  84. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C (2004) Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF{alpha} therapy. J Exp Med 3: 277–285

    Google Scholar 

  85. Dieckmann D, Bruett CH, Ploettner H, Lutz MB, Schuler G (2002) Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected]. J Exp Med 2: 247–253

    Google Scholar 

  86. Jonuleit H, Schmitt E, Kakirman H, Stassen M, Knop J, Enk AH (2002) Infectious tolerance: human CD25(+) regulatory T cells convey suppressor activity to conventional CD4(+) T helper cells. J Exp Med 2: 255–260

    Google Scholar 

  87. Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J, Masteller EL, McDevitt H, Bonyadi M, Bluestone JA (2004) In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 11: 1455–1465

    Google Scholar 

  88. Yamazaki S, Iyoda T, Tarbell K, Olson K, Velinzon K, Inaba K, Steinman RM (2003) Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J Exp Med 2: 235–247

    Google Scholar 

  89. Yamagiwa S, Gray JD, Hashimoto S, Horwitz DA (2001) A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 12: 7282–7289

    Google Scholar 

  90. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF (2004) Cutting edge: TGF-beta induces a regulatory phenotype in CD4+. J Immunol 9: 5149–5153

    Google Scholar 

  91. Lin CH, Hiinig T (2003) Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 3: 626–638

    Google Scholar 

  92. Prakken BJ, Samodal R, Le TD, Giannoni F, Yung GP, Scavulli J, Amox D, Roord S, de Kleer I, Bonnin D et al. (2004) Epitope-specific immunotherapy induces immune deviation of proinflammatory T cells in rheumatoid arthritis. Proc Natl Acad Sci USA 12:4228–4233

    Google Scholar 

  93. Horwitz DA, Zheng SG, Gray JD, Wang JH, Ohtsuka K, Yamagiwa S (2004) Regulatory T cells generated ex vivo as an approach for the therapy of autoimmune disease. Semin Immunol 2: 135–143

    Google Scholar 

  94. Qin S, Cobbold SP, Pope H, Elliott J, Kioussis D, Davies J, Waldmann H (1993) “Infectious” transplantation tolerance. Science 259: 974–977

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, 3508 GA, Utrecht, The Netherlands

    Jocea M. van Amelsfort & Johannes W. J. Bijlsma

  2. lnfection & Immunity Research Group, Franklin-Wilkins Building, King’s College London, 150 Stamford Street, London, SE1 9NN, UK

    Leonie S. Taams

Authors
  1. Jocea M. van Amelsfort
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Johannes W. J. Bijlsma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leonie S. Taams
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Infection & Immunity Research Group, Franklin-Wilkins Building, King’s College London, 150 Stamford Street, London, SE1 9NN, UK

    Leonie S. Taams

  2. Department of Immunohematology and Blood Transfusion, E3-Q, Leiden University Medical Center, Albinusdreef 2, P.O. Box 9600, 2300 RC, Leiden, The Netherlands

    Marca H. M. Wauben

  3. Department of Immunology and Molecular Pathology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London, W1T 4JF, UK

    Arne N. Akbar

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Birkhäuser Verlag Basel/Switzerland

About this chapter

Cite this chapter

van Amelsfort, J.M., Bijlsma, J.W.J., Taams, L.S. (2005). Immunotherapy of rheumatoid arthritis using CD4+CD25+ regulatory T cells. In: Taams, L.S., Wauben, M.H.M., Akbar, A.N. (eds) Regulatory T Cells in Inflammation. Progress in Inflammation Research. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7301-6_9

Download citation

Publish with us

Policies and ethics

Search

Navigation